MacPlus Federated Search is being upgraded to ACCESSSS Smart Search!

MacPlus Federated Search is in the process of being shut down. Its new and better successor, ACCESSSS Smart Search, will operate in its place.

An automated system can transfer your account to ACCESSSS Smart Search. To complete the transfer, which will migrate information such as your user profile, alert settings, saved articles, and recently alerted articles, simply enter your email and password below.

If you don't want to migrate your user account to ACCESSSS Smart Search that's cool too -- rest assured that when MacPlus Federated Search is completely shut down we will delete your user profile and all related data from our servers.

NB: This means you only have a limited amount of time to take us up on our offer of a one-click migration of all your MacPlus Federated Search user data to ACCESSSS Smart Search, so if you're on the fence, hurry up and decide!

Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018 Oct;159(10):1932-1954. doi: 10.1097/j.pain.0000000000001293.
Area Score
Family Medicine (FM)/General Practice (GP)
General Internal Medicine-Primary Care(US)
Special Interest - Pain -- Physician

This review examines evidence for the effectiveness of cannabinoids in chronic noncancer pain (CNCP) and addresses gaps in the literature by: considering differences in outcomes based on cannabinoid type and specific CNCP condition; including all study designs; and following IMMPACT guidelines. MEDLINE, Embase, PsycINFO, CENTRAL, and were searched in July 2017. Analyses were conducted using Revman 5.3 and Stata 15.0. A total of 91 publications containing 104 studies were eligible (n = 9958 participants), including 47 randomised controlled trials (RCTs) and 57 observational studies. Forty-eight studies examined neuropathic pain, 7 studies examined fibromyalgia, 1 rheumatoid arthritis, and 48 other CNCP (13 multiple sclerosis-related pain, 6 visceral pain, and 29 samples with mixed or undefined CNCP). Across RCTs, pooled event rates (PERs) for 30% reduction in pain were 29.0% (cannabinoids) vs 25.9% (placebo); significant effect for cannabinoids was found; number needed to treat to benefit was 24 (95% confidence interval [CI] 15-61); for 50% reduction in pain, PERs were 18.2% vs 14.4%; no significant difference was observed. Pooled change in pain intensity (standardised mean difference: -0.14, 95% CI -0.20 to -0.08) was equivalent to a 3 mm reduction on a 100 mm visual analogue scale greater than placebo groups. In RCTs, PERs for all-cause adverse events were 81.2% vs 66.2%; number needed to treat to harm: 6 (95% CI 5-8). There were no significant impacts on physical or emotional functioning, and low-quality evidence of improved sleep and patient global impression of change. Evidence for effectiveness of cannabinoids in CNCP is limited. Effects suggest that number needed to treat to benefit is high, and number needed to treat to harm is low, with limited impact on other domains. It seems unlikely that cannabinoids are highly effective medicines for CNCP.

Comments from MORE raters

Family Medicine (FM)/General Practice (GP) rater

This article should but probably won't dispel the widespread uncritical thinking that medical marijuana will provide effective and safe treatment for chronic non-cancer pain.

General Internal Medicine-Primary Care(US) rater

The proliferation of medically and legislatively sanctioned marijuana use absent clear evidence of benefit has long been a concern of mine and indeed, I believe it is a public health concern that is being inadequately confronted by the medical community. This article is a well-done and compelling contribution to the literature at least insofar as non-cancer chronic pain. State medical societies and physicians should be sure our legislators are aware of the medical facts regarding which conditions clearly benefit (as indeed some do) from access to medical marijuana and which ones do not and are being influenced by other social factors and advocacy groups.

General Internal Medicine-Primary Care(US) rater

An excellent meta-analysis that provides clinicians some estimates of the expected benefit when using cannabis to treat chronic noncancer pain. I believe this article will help general internists have more meaningful conversations with their patients about using marijuana for pain control.

Rheumatology rater

Not a particularly useful study, but that is the state of the art.

Special Interest - Pain -- Physician rater

"...NNTB is high, with NNTH low..." It's interesting to see the evidence of benefit is so weak with all the hype around.

Special Interest - Pain -- Physician rater

Probably the most comprehensive SR to date. Given the headlong rush to legalize and proliferate cannabis in many countries, this summary of evidence is extremely useful.

Special Interest - Pain -- Physician rater

Excellent article that will add to the controversy regarding medical marijuana and chronic pain treatment.